Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
Primary explants of human malignant melanoma were utilized in the preparation of oncolysates by Newcastle disease virus. The concentrated lysate, administered parenterally, was employed in an effort to augment antitumor immunologic responses in patients with metastatic melanoma. Observed cellular changes suggested a benefit, but humoral antibody measurements were not impressive.
D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000302:isolation & purification; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D007109:Immunity; D007167:Immunotherapy; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D008545:Melanoma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D009522:Newcastle disease virus; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D012882:Skin Tests; D013601:T-Lymphocytes; D014780:Viruses
D000951:Antigens, Neoplasm